Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027

Cogent Biosciences, Inc.

2024-Q1 EPS reported -$0.62

Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.
Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).
Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.
Completed oversubscribed private placement yielding $213.4M net proceeds.
Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cogent Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $58.3 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $58.3 million
Result: reported results

Exact text from the filing

Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.